141 related articles for article (PubMed ID: 18678496)
1. TX-2152: a conformationally rigid and electron-rich diyne analogue of FTY720 with in vivo antiangiogenic activity.
Nakayama S; Uto Y; Tanimoto K; Okuno Y; Sasaki Y; Nagasawa H; Nakata E; Arai K; Momose K; Fujita T; Hashimoto T; Okamoto Y; Asakawa Y; Goto S; Hori H
Bioorg Med Chem; 2008 Aug; 16(16):7705-14. PubMed ID: 18678496
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic activity of deoxoartemisinin derivatives on chorioallantoic membrane.
Jung M; Tak J; Chung WY; Park KK
Bioorg Med Chem Lett; 2006 Mar; 16(5):1227-30. PubMed ID: 16380253
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells.
Watanabe J; Endo Y; Shimada N; Natsume T; Sasaki T; Kobayashi M
In Vivo; 2007; 21(2):297-304. PubMed ID: 17436580
[TBL] [Abstract][Full Text] [Related]
4. Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.
Hanessian S; Charron G; Billich A; Guerini D
Bioorg Med Chem Lett; 2007 Jan; 17(2):491-4. PubMed ID: 17070046
[TBL] [Abstract][Full Text] [Related]
5. Semisynthesis and pharmacological activities of Tetrac analogs: angiogenesis modulators.
Bridoux A; Cui H; Dyskin E; Yalcin M; Mousa SA
Bioorg Med Chem Lett; 2009 Jun; 19(12):3259-63. PubMed ID: 19427201
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues.
Högenauer K; Billich A; Pally C; Streiff M; Wagner T; Welzenbach K; Nussbaumer P
ChemMedChem; 2008 Jul; 3(7):1027-9. PubMed ID: 18383466
[No Abstract] [Full Text] [Related]
7. An in vivo role for Trypanosoma cruzi calreticulin in antiangiogenesis.
Molina MC; Ferreira V; Valck C; Aguilar L; Orellana J; Rojas A; Ramirez G; Billetta R; Schwaeble W; Lemus D; Ferreira A
Mol Biochem Parasitol; 2005 Apr; 140(2):133-40. PubMed ID: 15760653
[TBL] [Abstract][Full Text] [Related]
8. Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
Nowak-Sliwinska P; van Beijnum JR; Casini A; Nazarov AA; Wagnieres G; van den Bergh H; Dyson PJ; Griffioen AW
J Med Chem; 2011 Jun; 54(11):3895-902. PubMed ID: 21534534
[TBL] [Abstract][Full Text] [Related]
9. 5'-O-tritylated nucleoside derivatives: inhibition of thymidine phosphorylase and angiogenesis.
Liekens S; Bronckaers A; Hernández AI; Priego EM; Casanova E; Camarasa MJ; Pérez-Pérez MJ; Balzarini J
Mol Pharmacol; 2006 Aug; 70(2):501-9. PubMed ID: 16675660
[TBL] [Abstract][Full Text] [Related]
10. A photoreactive analogue of the immunosuppressant FTY720.
Sun C; Bittman R
J Org Chem; 2006 Mar; 71(5):2200-2. PubMed ID: 16497020
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antiangiogenic activity of 6-amido-2,4,5-trimethylpyridin-3-ols.
Lee H; Banskota S; Kim DG; Been JH; Jin YJ; Gautam J; Jang H; Nam TG; Kim JA; Jeong BS
Bioorg Med Chem Lett; 2014 Jul; 24(14):3131-6. PubMed ID: 24894557
[TBL] [Abstract][Full Text] [Related]
12. Total synthesis of murisolins and evaluation of tumor-growth inhibitory activity.
Maezaki N; Tominaga H; Kojima N; Yanai M; Urabe D; Ueki R; Tanaka T; Yamori T
Chemistry; 2005 Oct; 11(21):6237-45. PubMed ID: 16075441
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.
Peifer C; Stoiber T; Unger E; Totzke F; Schächtele C; Marmé D; Brenk R; Klebe G; Schollmeyer D; Dannhardt G
J Med Chem; 2006 Feb; 49(4):1271-81. PubMed ID: 16480264
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of a key intermediate for the preparation of FTY720 analogs.
Hamada M; Adachi K; Hikawa H; Yokoyama Y
Chem Pharm Bull (Tokyo); 2012; 60(11):1395-8. PubMed ID: 23124563
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of daumone derivatives and their antiangiogenic activities on chorioallantoic membrane.
Ricci J; Min D; Oh M; Lim H; Chung WY; Park KK; Jung M
Med Chem; 2015; 11(8):747-52. PubMed ID: 25974079
[TBL] [Abstract][Full Text] [Related]
16. Preparation of antibodies against a novel immunosuppressant, FTY720, and development of an enzyme immunoassay for FTY720.
Matsumoto N; Kohno T; Uchida S; Shimizu T; Kusumoto H; Hirose R; Yanada K; Kurio W; Yamaguchi S; Watabe K; Fujita T
Bioorg Med Chem; 2006 Jun; 14(12):4182-92. PubMed ID: 16504516
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
Sensken SC; Bode C; Gräler MH
J Pharmacol Exp Ther; 2009 Mar; 328(3):963-9. PubMed ID: 19074680
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives.
Nagasawa H; Yamashita M; Mikamo N; Shimamura M; Oka S; Uto Y; Hori H
Comp Biochem Physiol A Mol Integr Physiol; 2002 May; 132(1):33-40. PubMed ID: 12062188
[TBL] [Abstract][Full Text] [Related]
19. A splicing isoform of LPP1, LPP1a, exhibits high phosphatase activity toward FTY720 phosphate.
Yamanaka M; Anada Y; Igarashi Y; Kihara A
Biochem Biophys Res Commun; 2008 Oct; 375(4):675-9. PubMed ID: 18755152
[TBL] [Abstract][Full Text] [Related]
20. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC
Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
